Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
XXB750 in Patients with Heart Failure
2023-504678-39-00Phase 2Completed
- Sponsor
- Novartis
- Start
- Mar 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 19
01
Overview
Phase 2, randomised, double-blind trial in heart failure (HF) comparing XXB750 plus standard of care, Placebo plus standard of care and Active-controlled standard of care comparator (3 arms). Primary endpoint: Change in log NT-proBNP from baseline to Week 16. Started Mar 2024; status: completed.
02
Drugs
xxb750
03
Conditions
heart failure (HF)
Beyond the preview
Go deeper on 2023-504678-39-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-504678-39-00.